Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lifts Unilever targets on 'best-in-class growth'

(Sharecast News) - Berenberg has lifted its target price for Unilever following the consumer-goods giant's 2024 results last week, predicting that "best-in-class growth" from the company will persist in 2025. Annual figures from the company on 13 February saw underlying sales growth of 4% meet analysts' expectations, with slightly better-than-expected pricing contribution of 1.3% (consensus: 1.1%) offsetting a slight miss with volume/mix growth of 2.7% (consensus: 2.9%).

Underlying operating margins came in at 18.4%, up 170 basis points on the previous year and slightly above the consensus forecast of 18.3%, helping underlying earnings per share rise 14.7% to €2.98, beating the €2.92 forecast.

Following the results, Berenberg raised its target price for the stock from 5,490p to 5,640p and reiterated a 'buy' rating.

"In our view, the investment case for Unilever remains strong. A quick review of 2024 highlights Unilever's best-in-class volume growth (2.9%), organic sales growth (4.2%), gross margin improvement (280bp), operating margin improvement (170bp), increase in brand marketing investments (up by 120bp to 15.5% of sales) and 15% EPS growth," the broker said.

"While this performance is unlikely to be replicated in 2025, we remain constructive on Unilever, which we expect will continue to deliver above-average growth (in volume, organic sales and EPS) versus industry peers such as Nestlé and P&G."

Berenberg has pencilled in 3.9% organic sales growth in 2025 along with 6% EPS growth, but highlighted that any signs of a turnaround in Unilever's struggling businesses in India, Latin America and Indonesia provide upside risk to these forecasts.

The shares were down 0.7% at 4,367p by 1302 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.